Clinical trials
Other Solid Tumors clinical trials
Below are recruiting other solid tumors clinical trials, each written for real people, not researchers. We’re tracking 1,667 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05882292RecruitingPhase 2
Study of a c-MET drug for advanced solid tumors
This Phase 2 trial tests whether a c-MET inhibitor can slow or shrink advanced solid tumors that have specific c-MET genetic changes. You may be eligible if your cancer has progressed after standard treatment and you meet safety and heart/health requirements.
Seoul, SeoulAges 19 years+ - NCT06408688RecruitingPhase 4
Mistletoe extract added to immunotherapy for advanced solid tumors
This trial tests whether adding mistletoe extract (Iscador) to standard immunotherapy can make the treatment safer and boost the immune system's response against advanced solid tumors (excluding skin cancer). If you are already receiving or about to start a checkpoint inhibitor, this study may help understand if the combination works better.
BadenAges 18 years+ - NCT07540572RecruitingPhase 1
Testing IDE574 safety and effectiveness in advanced solid tumors
This early-stage trial tests a new drug called IDE574 to see if it is safe and effective in treating advanced cancers that have spread or stopped responding to standard treatments. The trial focuses mainly on hormone-receptor positive breast cancer, but also includes lung, prostate, and colorectal cancers.
Plantation, FloridaAges 18–99 - NCT07538648RecruitingPhase 1
Imaging Dye for Surgery to Find Solid Tumors
This study tests a new injectable dye (NC527-X) that helps surgeons see tumors better during surgery. The dye glows under special light, making it easier to find and remove cancer tissue completely.
Hangzhou, ZhejiangAges 18 years+ - NCT07525141RecruitingPhase 1
Testing JNJ-1761981 for advanced solid tumors
This early-stage trial tests a new drug called JNJ-1761981 in people with solid tumors (cancers that form in organs or tissues, excluding brain tumors) that have spread or returned after standard treatment. The study aims to find the right dose and see how well the drug works.
Jacksonville, FloridaAges 18 years+ - NCT07529808RecruitingPhase 1/Phase 2
New Drug BHB810 for Advanced Stomach Cancer
This trial tests a new drug called BHB810 for gastric (stomach) and gastroesophageal junction cancer that has stopped responding to standard treatments or has no standard options available. The drug targets a protein called CDH17 found on cancer cells and may help slow or shrink the tumor.
Duarte, CaliforniaAges 18 years+ - NCT07533708RecruitingPhase 1
Testing HLX3902 for advanced cancers, especially prostate cancer
This study tests a new drug called HLX3902 in patients with advanced cancers that have stopped responding to standard treatments. The drug targets a protein called STEAP1 and may help slow or stop cancer growth.
NanchangAges 18 years+ - NCT07532902RecruitingPhase 1
BMS-986504 with standard treatment for advanced solid tumors
This trial tests a new drug called BMS-986504 alongside standard treatments for certain advanced cancers (mesothelioma, stomach/esophageal cancer, or bladder cancer). The drug targets a specific genetic change (MTAP deletion) that may make cancer cells more vulnerable to treatment. Joining could help you access a new therapy, but it may not be suitable for everyone.
Basking Ridge, New JerseyAges 18 years+ - NCT07522073RecruitingPhase 3
Chemotherapy with or without KRAS inhibitor for pancreatic cancer
This study tests whether adding a new drug called INCB161734 to standard chemotherapy helps people with advanced pancreatic cancer that has a specific genetic change (KRAS G12D mutation). You would be randomly assigned to receive either chemotherapy alone or chemotherapy plus the new drug.
Birmingham, AlabamaAges 18 years+ - NCT07518043RecruitingPhase 1
HLX18 vs. Opdivo after surgery for solid tumors
This trial compares two immune-boosting drugs (HLX18 and Opdivo, also called nivolumab) in patients who have had surgery to remove certain cancers—including esophageal, melanoma, or bladder cancer—with no signs of cancer remaining. The goal is to see which drug helps prevent the cancer from coming back.
FuzhouAges 18–70 - NCT07519655RecruitingPhase 1
New Cancer Drug Treatment for Advanced Lung, Esophageal, or Skin Cancer
This study tests a new drug called PF-08046033 in people with advanced lung cancer (NSCLC), esophageal cancer (ESCC), or melanoma (skin cancer) that has spread or can't be surgically removed. The drug targets a specific protein to help slow or stop cancer growth.
Denver, ColoradoAges 18 years+ - NCT07523529RecruitingPhase 1/Phase 2
CAR-T Cell Therapy for Advanced Solid Tumors
This trial tests a new type of immune cell therapy (CAR-T cells) designed to target two markers on cancer cells at once. The goal is to help patients with advanced solid tumors where standard treatments have stopped working or aren't an option.
Shenzhen, GuangdongAges 18–75 - NCT07514065RecruitingPhase 1
TSL2109 Safety and Effectiveness Study in Advanced Cancers
This early-stage study tests a new drug called TSL2109 in patients with advanced solid cancers that haven't responded to standard treatment. Researchers want to find the right dose, understand how the body processes it, and see if it can slow or shrink tumors, with special focus on certain prostate and breast cancers.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07510321Recruiting
A study of FL-261 imaging for cancer diagnosis
This trial tests a new imaging agent called FL-261 to help doctors see and stage cancers more clearly. If you have a known or suspected cancer like lung, colon, or head and neck cancer, this study may improve how your cancer is evaluated.
Wuhan, HubeiAges 18 years+ - NCT07503808RecruitingPhase 1
IDE034 for advanced solid tumors with B7-H3 or PTK7
This study tests a new drug called IDE034 for people with advanced solid tumors that have certain markers (B7-H3 and PTK7). The drug may help by targeting these markers on cancer cells, and the study checks if it is safe and effective.
Denver, ColoradoAges 18 years+ - NCT07498725RecruitingPhase 1/Phase 2
Study of LRK-4189 for solid tumors that have spread or can't be removed
This trial tests a new drug called LRK-4189, alone or with other treatments, for people with advanced solid tumors that have worsened despite prior therapy. The goal is to see if it is safe, tolerable, and helpful against the cancer.
NiceAges 18 years+ - NCT07488676RecruitingPhase 1/Phase 2
Study of ASP546C for stomach, pancreas, and other cancers
This trial tests a new drug called ASP546C in people with certain advanced cancers that have a specific marker (CLDN18.2). It aims to see if the drug can shrink or slow tumor growth.
Birmingham, AlabamaAges 18 years+ - NCT07486713RecruitingPhase 4
Olutasidenib drug interaction study for IDH1 mutation cancers
This trial tests how olutasidenib interacts with other drugs in people with cancers that have an IDH1 mutation, like certain leukemias or brain tumors. Participation may help determine the best way to take this treatment safely.
Orange, CaliforniaAges 18 years+ - NCT07483554RecruitingPhase 2
IBI343 combination therapy for advanced solid tumors
This trial tests a new drug called IBI343 combined with other treatments for people with advanced solid tumors that are CLDN18.2-positive. It aims to see if the combination can help shrink or control the cancer.
Hangzhou, ZhejiangAges 18 years+ - NCT07483658Recruiting
Salvage pelvic radiotherapy: 20 vs 25 sessions for recurring prostate cancer
This trial compares two schedules of pelvic radiotherapy for men whose prostate cancer has returned after surgery. Both schedules aim to control the cancer with fewer visits for one of them.
Gatineau, QuebecAges 18 years+ - NCT07487168RecruitingPhase 1
PIPAC with mitomycin for peritoneal cancer
This trial tests a new way to deliver chemotherapy directly into the abdomen (called PIPAC) for people with cancer spread to the lining of the belly. It uses the drug mitomycin and is for patients who cannot have standard surgery or heated chemotherapy.
Tampa, FloridaAges 18 years+ - NCT07484932Recruiting
Tailored Treatment Dosing for Older Adults with Cancer
This trial tests a new dosing strategy (called TRTRM or ACTTOP) to find the right amount of cancer treatment for patients aged 65 and older. It aims to reduce side effects while keeping the treatment effective.
Hong KongAges 65 years+ - NCT06758557RecruitingPhase 1/Phase 2
HB0025 for advanced solid tumors
This trial tests a new drug called HB0025 for people with advanced non-small cell lung cancer or endometrial cancer that cannot be removed by surgery. The study aims to see if the drug is safe and effective.
Baoding, HebeiAges 18–75 - NCT07470853RecruitingPhase 1
Study of HWK-016 for advanced ovarian or endometrial cancer
This trial tests a new drug called HWK-016, which is designed to target and deliver medicine directly to cancer cells that have a specific marker (MUC16). It is for people with advanced ovarian or endometrial cancer to see if it can shrink tumors or slow their growth.
Little Rock, ArkansasAges 18 years+
Hear when a new Other Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for other solid tumors?
- Yes. Clin2 currently lists 1,667 recruiting other solid tumors studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a other solid tumors trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a other solid tumors trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.